Gene Found Activated In 70 Of Prostate Cancer Cases
Gene Found Activated In 70% of Prostate Cancer Cases
In addition to Berg and Schwartz, the team of authors includes Drs.Yan-Gao Man, Department of Gynecologic and Breast Pathology, The Armed Forces Institute of Pathology, Washington DC; M Katayoon Rezaei, Department of Pathology, The George Washington University Medical Center, Washington DC; and Samuel J Simmens, Department of Biostatistics, The George Washington University Medical Center, Washington DC.
Berg had previously published and reported, and the authors cite in the current article, that BP1 is activated in a majority of breast cancer (80%) and acute myeloid leukemia (63%) cases. The authors say, “Our current and past findings suggest that BP1 may be an important regulatory factor in the oncogenic pathway of several malignancies including prostate cancer.” Berg stated today, “BP1 is a new, potentially significant target for therapy. It could be an important new diagnostic marker for prostate cancer and the other cancers in which it is expressed.”
Prostate cancer is the leading cancer among men. The National Cancer Institute estimates 186,320 new cases and 28,660 deaths from prostate cancer in the U.S. in 2008. The article is titled, “BP1, a homeoprotein, is significantly expressed in prostate adenocarcinoma and is concordant with prostatic intraepithelial neoplasia.” The article is also available as “advance online publication” (Citation: Modern Pathology advance online publication 17 October 2008; doi: 10.1038/modpathol.2008.168). Link to abstract: https://www.nature.com/doifinder/10.1038/modpathol.2008.168.
For more free information about prostate cancer or breast cancer, please contact the attorneys at Berger & Lagnese, LLC in Pittsburgh, Pennsylvania.